Axsome Therapeutics, Inc. (AXSM) Stock AnalysisAXSMStock AnalysisAxsome Therapeutics, Inc.

Axsome Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company focused on developing medicines for people impacted by central nervous system (CNS) conditions. Its commercial products include AUVELITY, SUNOSI, and SYMBRAVO. It is also advancing pipeline of novel product candidates in early- to late-stage development addressing a broad range of serious neurological and psychiatric conditions. Its product pipelines include AXS-05, AXS-12, and AXS-14. Its lead product candidate, AXS-05 (dextromethorphan-bupropion), is developed for the treatment of Alzheimer’s disease (AD) agitation and smoking cessation. Its AXS-12 (reboxetine) is a novel, oral, potent, highly selective investigational norepinephrine reuptake inhibitor (NRI) and cortical dopamine modulator being developed for the treatment of narcolepsy. Its AXS-14 (esreboxetine) is a novel, oral, potent, highly selective investigational NRI being developed for the management of fibromyalgia. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Axsome Therapeutics is currently a hold. The stock has a current price of $199.02 and an RSI of 19.79, indicating it is oversold. However, the forward P/E ratio is extremely high at 370.37, suggesting that the stock may be overvalued at this time. While the company reported a strong 46% year-over-year revenue increase in Q2, reaching $218.4 million, and has a gross margin of 93.06%, the significant net losses and high forward P/E ratio raise concerns about its valuation. The main risk is the high forward P/E ratio of 370.37, which could indicate that the stock is overvalued if growth does not meet expectations.

2 analysts cover AXSM: 2 rate it Buy, 0 Hold and 0 Sell. The average price target is 209.54.